WO2018098352A3 - Ciblage d'expression du point de contrôle immunitaire induit par kras - Google Patents

Ciblage d'expression du point de contrôle immunitaire induit par kras Download PDF

Info

Publication number
WO2018098352A3
WO2018098352A3 PCT/US2017/063116 US2017063116W WO2018098352A3 WO 2018098352 A3 WO2018098352 A3 WO 2018098352A3 US 2017063116 W US2017063116 W US 2017063116W WO 2018098352 A3 WO2018098352 A3 WO 2018098352A3
Authority
WO
WIPO (PCT)
Prior art keywords
kras
signaling
immune checkpoint
tumor cells
immunotherapeutic agent
Prior art date
Application number
PCT/US2017/063116
Other languages
English (en)
Other versions
WO2018098352A2 (fr
Inventor
Jun Oishi
Xiangao Sun
Chiang J. Li
Original Assignee
Jun Oishi
Xiangao Sun
Li Chiang J
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jun Oishi, Xiangao Sun, Li Chiang J filed Critical Jun Oishi
Publication of WO2018098352A2 publication Critical patent/WO2018098352A2/fr
Publication of WO2018098352A3 publication Critical patent/WO2018098352A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Abstract

L'interaction de PD-L1 exprimée sur la surface de cellules tumorales déclenche une signalisation PD-1 dans des lymphocytes T qui contribue à la résistance de cancers à des thérapies de points de contrôle immunitaires émergents. La présente invention démontre que la signalisation RAF/MEK/ERK/FRA induite par KRAS est requise pour l'expression génique PD-L1 dans des cellules tumorales. L'invention concerne ainsi des compositions pour le traitement du cancer comprenant des modulateurs de la signalisation de KRAS combinés à un agent immunothérapeutique qui restaure la sensibilité de cellules tumorales résistantes à l'agent immunothérapeutique. Par exemple, une combinaison d'ARN interférents asymétriques (ARNai) spécifiques de KRAS et d'un inhibiteur de point de contrôle immunitaire s'est révélée améliorer la cytotoxicité des lymphocytes T spécifiques aux cellules tumorales. L'invention concerne également des méthodes permettant d'augmenter l'efficacité thérapeutique de traitements anticancéreux existants par co-administration d'un modulateur de signalisation KRAS.
PCT/US2017/063116 2016-11-22 2017-11-22 Ciblage d'expression du point de contrôle immunitaire induit par kras WO2018098352A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662425358P 2016-11-22 2016-11-22
US62/425,358 2016-11-22

Publications (2)

Publication Number Publication Date
WO2018098352A2 WO2018098352A2 (fr) 2018-05-31
WO2018098352A3 true WO2018098352A3 (fr) 2018-07-05

Family

ID=60703090

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/063116 WO2018098352A2 (fr) 2016-11-22 2017-11-22 Ciblage d'expression du point de contrôle immunitaire induit par kras

Country Status (1)

Country Link
WO (1) WO2018098352A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3717487A1 (fr) 2017-12-01 2020-10-07 The Board of Trustees of the University of Illinois Modificateurs épigénétiques à base de pyridinone et leurs utilisations
US20210220471A1 (en) * 2018-07-13 2021-07-22 Memorial Sloan Kettering Cancer Center Methods of using pharmacologic inhibitors of type 2 cytokine signaling to treat or prevent pancreatic cancer
WO2020081905A1 (fr) * 2018-10-18 2020-04-23 Jounce Therapeutics, Inc Méthodes de traitement du cancer
US20220154189A1 (en) * 2019-03-29 2022-05-19 Dicerna Pharmaceuticals, Inc. Compositions and methods for the treatment of kras associated diseases or disorders
US20220288201A1 (en) * 2019-07-22 2022-09-15 H. Lee Moffitt Cancer And Research Institute, Inc. Combination therapy for treating ras-mutant cancers
US11890285B2 (en) 2019-09-24 2024-02-06 Mirati Therapeutics, Inc. Combination therapies
WO2023087012A1 (fr) * 2021-11-15 2023-05-19 The Board Of Trustees Of The University Of Illinois Méthode de traitement d'un cancer lié à une mutation ras
WO2023172940A1 (fr) * 2022-03-08 2023-09-14 Revolution Medicines, Inc. Méthodes de traitement du cancer du poumon réfractaire immunitaire

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050260167A1 (en) * 2004-04-27 2005-11-24 Japan Health Sciences Foundation Interferon alpha and antisense K-ras RNA combination gene therapy
US20130302407A1 (en) * 2012-05-09 2013-11-14 Gradalis, Inc. Bi-Functional Short-Hairpin RNA (Bi-shRNA) Specific for Single-Nucleotide KRAS Mutations
WO2014195852A1 (fr) * 2013-06-03 2014-12-11 Glaxosmithkline Intellectual Property (No.2) Limited Combinaisons d'un anticorps anti-pd-l1 et d'un inhibiteur de mek et/ou d'un inhibiteur de braf
WO2015164818A1 (fr) * 2014-04-25 2015-10-29 Strike Bio, Inc. Arni à cibles multiples permettant le traitement de cancers
US20160108123A1 (en) * 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US5028527A (en) 1988-02-22 1991-07-02 Applied Bio Technology Monoclonal antibodies against activated ras proteins with amino acid mutations at position 13 of the protein
US5081230A (en) 1987-07-08 1992-01-14 E. I. Dupont Denemours And Company Monoclonal antibodies reactive with normal and oncogenic forms of the ras p21 protein
US5084380A (en) 1985-01-29 1992-01-28 Applied Biotechnology Monoclonal antibodies reactive with activated and oncogenic ras p21 proteins
US4898932A (en) 1985-01-29 1990-02-06 E. I. Du Pont De Nemours And Company Monoclonal antibodies reactive with activated and oncogenic ras p21 proteins
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4820631A (en) 1986-07-30 1989-04-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Deletion mutants and monoclonal antibodies against ras proteins
US5112737A (en) 1988-02-22 1992-05-12 Applied Biotechnology, Inc. Monoclonal antibodies against activated ras proteins with amino acid mutations at position 13 of the protein
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
US5225347A (en) 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Therapeutic ribozyme compositions and expression vectors
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5965539A (en) 1993-05-18 1999-10-12 Univeristy Of Pittsburgh Inhibitors of prenyl transferases
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
US5861510A (en) 1995-04-20 1999-01-19 Pfizer Inc Arylsulfonyl hydroxamic acid derivatives as MMP and TNF inhibitors
US5693773A (en) 1995-06-07 1997-12-02 Hybridon Incorporated Triplex-forming antisense oligonucleotides having abasic linkers targeting nucleic acids comprising mixed sequences of purines and pyrimidines
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
TR199900066T2 (xx) 1996-07-18 1999-04-21 Pfizer Inc. Matriks metalloproteazlar�n fosfinat bazl� inhibit�rleri
CA2264284A1 (fr) 1996-08-23 1998-02-26 Ralph P. Robinson Derives de l'acide arylsulfonylamino hydroxamique
PT950059E (pt) 1997-01-06 2004-10-29 Pfizer Derivados de sulfona ciclicos
PT977733E (pt) 1997-02-03 2003-12-31 Pfizer Prod Inc Derivados de acido arilsulfonilamino-hidroxamico
CA2279863A1 (fr) 1997-02-07 1998-08-13 Pfizer Inc. Derives du n-hxdroxy-beta-sulfonyl-propionamide et leur utilisation comme inhibiteurs des metalloproteases matrices
AU722784B2 (en) 1997-02-11 2000-08-10 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
CN1371416B (zh) 1999-08-24 2012-10-10 梅达里克斯公司 人ctla-4抗体及其应用
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US6124133A (en) 1999-10-15 2000-09-26 Isis Pharmaceuticals Inc. Antisense inhibition of fra-1 expression
KR100909681B1 (ko) 2000-12-01 2009-07-29 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자
AU2003234736B2 (en) 2002-04-12 2008-09-25 E. R. Squibb & Sons, L.L.C. Methods of treatment using CTLA-4 antibodies
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
DK2206517T3 (da) 2002-07-03 2023-11-06 Ono Pharmaceutical Co Immunpotentierende sammensætninger omfattende af anti-PD-L1-antistoffer
WO2004024940A2 (fr) 2002-09-16 2004-03-25 University Of Southern California Modulation d'un gene mediee par arn
US7750144B2 (en) 2003-06-02 2010-07-06 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of RNA silencing
EP1732600A2 (fr) 2004-03-26 2006-12-20 Pfizer Products Incorporated Utilisations d'anticorps anti-ctla-4
US20060099203A1 (en) 2004-11-05 2006-05-11 Pease Larry R B7-DC binding antibody
AU2005300315A1 (en) 2004-11-04 2006-05-11 Pfizer Products Inc. CTLA-4 antibody and aromatase inhibitor or combination treatment for breast cancer
DK2620450T3 (en) 2005-03-08 2019-02-04 Pfizer Prod Inc Antibody Compositions against CTLA-4
CA2602316A1 (fr) 2005-03-23 2006-09-28 Pfizer Products Inc. Association d'anticorps anti-ctla4 et d'indolinone dans le traitement du cancer
EP1868644A1 (fr) 2005-03-23 2007-12-26 Pfizer Products Incorporated Traitement du cancer de la prostate au moyen d'anticorps anti-ctla4 et d'une hormonotherapie
CA2607147C (fr) 2005-05-09 2018-07-17 Ono Pharmaceutical Co., Ltd. Anticorps monoclonaux humains pour mort programmee 1 (mp-1) et procedes pour traiter le cancer en utilisant des anticorps anti-mp-1 seuls ou associes a d'autres immunotherapies
JP5252635B2 (ja) 2005-07-01 2013-07-31 メダレックス インコーポレーティッド プログラム死リガンド１（ｐｄ−ｌ１）に対するヒトモノクローナル抗体
WO2007056539A2 (fr) 2005-11-08 2007-05-18 Medarex, Inc. Prevention et traitement de l'enterocolite associee a un traitement par anticorps anti-ctla-4
NZ568016A (en) 2005-12-07 2011-12-22 Medarex Inc CTLA-4 antibody dosage escalation regimens
WO2007113648A2 (fr) 2006-04-05 2007-10-11 Pfizer Products Inc. Polythérapie à base d'un anticorps anti-ctla4
EP2025347A4 (fr) 2006-05-15 2010-08-11 Takeda Pharmaceutical Agent prophylactique et thérapeutique contre le cancer
EP2134375A2 (fr) 2007-03-07 2009-12-23 Cold Spring Harbor Laboratory ARNpi ET UTILISATIONS CORRESPONDANTES
CN104945508B (zh) 2007-06-18 2019-02-22 默沙东有限责任公司 针对人程序性死亡受体pd-1的抗体
EP2201022A4 (fr) 2007-08-27 2012-01-04 Boston Biomedical Inc Composition d'arn duplex asymétrique utile comme mimétique ou inhibiteur de micro arn
CN101848908B (zh) 2007-09-06 2014-07-02 北京强新生物科技有限公司 激酶抑制剂的组合物及其在治疗癌症和其它与激酶相关的疾病中的用途
JP5872160B2 (ja) 2007-09-10 2016-03-01 ボストン バイオメディカル， インコーポレイテッド 癌治療のための新規の組成物および方法
WO2009089260A2 (fr) 2008-01-08 2009-07-16 Bristol-Myers Squibb Company Combinaison d'anticorps anti-ctla4 avec des agents de modulation de la tubuline pour le traitement de maladies prolifératives
EP2240204A1 (fr) 2008-02-04 2010-10-20 Medarex, Inc. Anticorps anti-clta-4 avec blocage réduit de la liaison de ctla-4 à b7 et leurs utilisations
CN104548091A (zh) 2008-02-11 2015-04-29 治疗科技公司 用于肿瘤治疗的单克隆抗体
GB0807065D0 (en) 2008-04-18 2008-05-21 Univ Leeds Novel scaffolds
WO2009143372A2 (fr) 2008-05-21 2009-11-26 Intradigm Corporation Compositions comportant des arnsi des gènes a-raf, b-raf, et c-raf et leurs procédés d’utilisation
WO2010014784A2 (fr) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combinaison d'anticorps anti-ctla4 avec divers régimes thérapeutiques pour un traitement synergétique de maladies prolifératives
BRPI0917891A2 (pt) 2008-08-25 2015-11-24 Amplimmune Inc antagonistas de pd-1 e métodos de utilização dos mesmos
EP3133086B1 (fr) 2008-09-26 2018-08-01 Dana-Farber Cancer Institute, Inc. Anticorps humains anti-pd-1, pd-l1 et pd-l2 et leurs utilisations
WO2010042433A1 (fr) 2008-10-06 2010-04-15 Bristol-Myers Squibb Company Combinaison d'anticorps cd137 et d'anticorps ctla-4 pour le traitement de maladies prolifératives
LT4209510T (lt) 2008-12-09 2024-03-12 F. Hoffmann-La Roche Ag Anti-pd-l1 antikūnai ir jų panaudojimas t ląstelių funkcijos pagerinimui
HUE033312T2 (en) 2009-07-20 2017-11-28 Bristol Myers Squibb Co Combination of anti CTLA4 antibody with etoposide for synergistic treatment of proliferative diseases
US8435516B2 (en) 2009-10-12 2013-05-07 Pfizer Inc. Cancer treatment
KR101237036B1 (ko) 2009-11-04 2013-02-25 성균관대학교산학협력단 안티센스 가닥에 의한 오프-타겟 효과를 최소화한 신규한 ｓｉＲＮＡ 구조 및 그 용도
PT2504364T (pt) 2009-11-24 2017-11-14 Medimmune Ltd Agentes de ligação direcionados contra b7-h1
EP2504028A4 (fr) 2009-11-24 2014-04-09 Amplimmune Inc Inhibition simultanée de pd-l1/pd-l2
MX370721B (es) 2010-03-19 2019-12-20 Boston Biomedical Inc Star Compuestos y composiciones novedosas para atacar las células madre del cáncer.
CN103025159A (zh) 2010-03-19 2013-04-03 波士顿生物医学公司 靶向癌症干细胞的新方法
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
US9783578B2 (en) 2010-06-25 2017-10-10 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
WO2012018881A2 (fr) 2010-08-03 2012-02-09 Alnylam Pharmaceuticals, Inc. Procédés et compositions pour la régulation d'arn
WO2012027536A1 (fr) 2010-08-26 2012-03-01 Bristol-Myers Squibb Company Combinaison d'anticorps anti-ctla4 avec des inhibiteurs de braf pour le traitement synergique de maladies prolifératives
JP2014511384A (ja) 2011-03-04 2014-05-15 ゾウシャン ハイジョンジョウ シンシェン ファーマシューティカルズ カンパニー リミテッド 疾患治療のための４，９−ジヒドロキシ−ナフト［２，３−ｂ］フランの新規エステル
PT2691112T (pt) 2011-03-31 2018-07-10 Merck Sharp & Dohme Formulações estáveis de anticorpos para o recetor pd-1 humano de morte programada e tratamentos relacionados
CA2833636A1 (fr) 2011-04-20 2012-10-26 Amplimmune, Inc. Anticorps et autres molecules qui se lient a b7-h1 et a pd-1
CN103732238A (zh) 2011-06-08 2014-04-16 奥瑞基尼探索技术有限公司 用于免疫调节的治疗性化合物
JP6240600B2 (ja) 2011-07-24 2017-11-29 キュアテク リミテッド ヒト化免疫モノクローナル抗体の変異体
WO2013019620A2 (fr) 2011-07-29 2013-02-07 Glaxosmithkline Llc Méthode de traitement du cancer au moyen d'une combinaison contenant un inhibiteur de braf, un inhibiteur de mek et un anticorps anti-ctla-4
WO2013059320A1 (fr) 2011-10-17 2013-04-25 Board Of Regents, The University Of Texas System Traitement de cancers caractérisés par la présence d'une protéine npm1 mutante au moyen d'inhibiteurs de mek
US8977803B2 (en) 2011-11-21 2015-03-10 Western Digital Technologies, Inc. Disk drive data caching using a multi-tiered memory
AU2012344260B2 (en) 2011-11-28 2017-09-07 Merck Patent Gmbh Anti-PD-L1 antibodies and uses thereof
WO2013132317A1 (fr) 2012-03-07 2013-09-12 Aurigene Discovery Technologies Limited Composés peptidomimétiques utilisés comme immunomodulateurs
US20150079100A1 (en) 2012-03-23 2015-03-19 Bristol-Myers Squibb Company Methods of treatments using ctla-4 antibodies
CN104245726A (zh) 2012-03-29 2014-12-24 奥瑞基尼探索技术有限公司 来自人pd1的bc环的免疫调节环状化合物
CA2873402C (fr) 2012-05-15 2023-10-24 Bristol-Myers Squibb Company Immunotherapie anticancereuse par rupture de la signalisation pd-1/pd-l1
CN104936982B (zh) 2012-08-03 2020-04-24 丹娜法伯癌症研究院 抗-pd-l1和pd-l2双结合抗体单一试剂及其使用方法
CN103172744B (zh) 2012-09-28 2016-01-13 武汉纽斯特生物技术有限公司 特异性识别B-Raf突变蛋白的单克隆抗体、制备方法及其应用
WO2014066532A1 (fr) 2012-10-23 2014-05-01 Bristol-Myers Squibb Company Association d'anticorps anti-kir et anti-ctla-4 pour le traitement du cancer
US9115122B2 (en) 2012-12-20 2015-08-25 University Of Maryland, Baltimore Non-ATP dependent inhibitors of extracellular signal-regulated kinase (ERK)
JP6507102B2 (ja) 2013-02-05 2019-04-24 １グローブ ヘルス インスティテュート エルエルシー 薬物送達キャリアとしての生分解性でかつ臨床上適合性のナノ粒子
US9187454B2 (en) 2013-03-13 2015-11-17 Boston Biomedical, Inc. Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof
SG11201507346PA (en) 2013-03-13 2015-10-29 Boston Biomedical Inc 3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer
EP3401314B1 (fr) 2013-03-15 2023-11-08 Araxes Pharma LLC Inhibiteurs covalents de kras g12c
JP6433085B2 (ja) 2013-04-09 2018-12-05 ボストン バイオメディカル， インコーポレイテッド がんの処置に使用するための２−アセチルナフト［２，３−ｂ］フラン−４，９−ジオン
MX2015015037A (es) 2013-05-02 2016-07-08 Anaptysbio Inc Anticuerpos dirigidos contra la proteina muerte programada-1 (pd-1).
SG10201709715RA (en) 2013-05-24 2017-12-28 Medimmune Llc Anti-b7-h5 antibodies and their uses
AU2014274660B2 (en) 2013-06-06 2019-05-16 Pierre Fabre Médicament Anti-C10orf54 antibodies and uses thereof
US20170015718A1 (en) 2013-07-03 2017-01-19 Universite Pierre Et Marie Curie (Paris 6) Pro-apoptotic ras and raf peptides
AU2014315457B2 (en) 2013-09-04 2018-05-10 Bristol-Myers Squibb Company Compounds useful as immunomodulators
PT3363790T (pt) 2013-09-06 2020-05-06 Aurigene Discovery Tech Ltd Derivados 1,2,4-oxadiazoles como imunomoduladores
PL3041468T3 (pl) 2013-09-06 2018-12-31 Aurigene Discovery Technologies Limited Pierścieniowe związki peptydomimetyczne jako immunomodulatory
AU2014316684A1 (en) 2013-09-06 2016-04-28 Aurigene Discovery Technologies Limited 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators
BR112016005303A2 (pt) 2013-09-11 2017-09-12 Medimmune Ltd anticorpos anti-b7-h1 para tratamento de tumores
CN112457403B (zh) 2013-09-13 2022-11-29 广州百济神州生物制药有限公司 抗pd1抗体及其作为治疗剂与诊断剂的用途
US10130590B2 (en) 2013-10-01 2018-11-20 Dana-Farber Cancer Institute, Inc. Methods of treating cancer with atovaquone-related compounds
PT3712174T (pt) 2013-12-24 2022-05-27 Janssen Pharmaceutica Nv Anticorpos e fragmentos anti-vista
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
CN106255510A (zh) 2014-03-05 2016-12-21 百时美施贵宝公司 使用抗pd‑1抗体与另一抗癌剂的组合治疗肾癌
TW201620525A (zh) 2014-03-14 2016-06-16 波士頓生醫公司 使ｋ－ｒａｓ靜默之非對稱干擾ｒｎａ組成物及其使用方法
PL3142751T3 (pl) 2014-05-13 2019-12-31 Medimmune Limited Przeciwciała anty-b7-h1 i anty-ctla-4 do leczenia niedrobnokomórkowego nowotworu płuca
WO2016030455A1 (fr) 2014-08-28 2016-03-03 Medimmune Limited Anticorps anti-b7-h1 et anti-ctla -4 pour le traitement du cancer du poumon non à petites cellules
ES2826443T3 (es) 2014-09-25 2021-05-18 Araxes Pharma Llc Inhibidores de proteínas mutantes KRAS G12C
DK3229838T3 (da) 2014-12-11 2020-10-19 Pf Medicament Anti-C10orf54-antistoffer og anvendelser deraf
US20180214449A1 (en) 2015-01-30 2018-08-02 Ubrx, Inc. Cancer therapy using jak inhibitor in combination with mapk inhibitors
KR20170132171A (ko) 2015-02-26 2017-12-01 메르크 파텐트 게엠베하 암 치료를 위한 ｐｄ­１ ／ ｐｄ­ｌ１ 저해제
EA201791629A1 (ru) 2015-03-10 2018-02-28 Ауриджен Дискавери Текнолоджис Лимитед 1,3,4-оксадиазольные и тиадиазольные соединения в качестве иммуномодуляторов
CA2979161A1 (fr) 2015-03-10 2016-09-15 Aurigene Discovery Technologies Limited Composes 3-substitue -1,2,4-oxadiazole et thiadiazole utilises comme immunomodulateurs
ES2907988T3 (es) 2015-03-10 2022-04-27 Aurigene Discovery Tech Ltd Compuestos de 1,2,4-oxadiazol y tiadiazol como inmunomoduladores
CN107427491A (zh) 2015-03-10 2017-12-01 奥瑞基尼探索技术有限公司 作为免疫调节剂的治疗性环状化合物
CN107427497A (zh) 2015-03-10 2017-12-01 奥瑞基尼探索技术有限公司 作为免疫调节剂的3‑取代的1,3,4‑噁二唑和噻二唑化合物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050260167A1 (en) * 2004-04-27 2005-11-24 Japan Health Sciences Foundation Interferon alpha and antisense K-ras RNA combination gene therapy
US20130302407A1 (en) * 2012-05-09 2013-11-14 Gradalis, Inc. Bi-Functional Short-Hairpin RNA (Bi-shRNA) Specific for Single-Nucleotide KRAS Mutations
WO2014195852A1 (fr) * 2013-06-03 2014-12-11 Glaxosmithkline Intellectual Property (No.2) Limited Combinaisons d'un anticorps anti-pd-l1 et d'un inhibiteur de mek et/ou d'un inhibiteur de braf
WO2015164818A1 (fr) * 2014-04-25 2015-10-29 Strike Bio, Inc. Arni à cibles multiples permettant le traitement de cancers
US20160108123A1 (en) * 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
E. ZORDE KHVALEVSKY ET AL: "Mutant KRAS is a druggable target for pancreatic cancer", PROCEEDINGS NATIONAL ACADEMY OF SCIENCES PNAS, vol. 110, no. 51, 2 December 2013 (2013-12-02), US, pages 20723 - 20728, XP055460351, ISSN: 0027-8424, DOI: 10.1073/pnas.1314307110 *
FLEMING JASON B ET AL: "Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy", MOLECULAR CANCER RESEARCH, vol. 3, no. 7, 1 July 2005 (2005-07-01), AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, pages 413 - 423, XP002532582, ISSN: 1541-7786, DOI: 10.1158/1541-7786.MCR-04-0206 *
FRUEHAUF JOHANNES ET AL: "Simultaneous silencing of key oncogenic pathways - A promising novel approach to colon cancer treatment", GASTROENTEROLOGY, vol. 130, no. 4, Suppl. 2, 1 April 2006 (2006-04-01), W.B. SAUNDERS CO, US, pages A681 - A682, XP002774825, ISSN: 0016-5085 *
HIDETOSHI SUMIMOTO ET AL: "RAS-Mitogen-Activated Protein Kinase Signal Is Required for Enhanced PD-L1 Expression in Human Lung Cancers", PLOS ONE, vol. 11, no. 11, E0166626, 15 November 2016 (2016-11-15), pages 1 - 18, XP055460571, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0166626 *
JONG WOO LEE ET AL: "Abstract 2334: Anti-cancer efficacy of the combination with immunomodulatory antibodies and MEK inhibitor for Kras mutation and p53 knockout driven lung cancer", CANCER RESEARCH, vol. 76, no. 14 Suppl., July 2016 (2016-07-01), 107TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-CANCER-RESEARCH (AACR); NEW ORLEANS, LA, USA; APRIL 16 -20, 2016, XP002779275, DOI: 10.1158/1538-7445.AM2016-2334 *
LI YI ET AL: "Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy", LEUKEMIA & LYMP, vol. 53, no. 10, 1 October 2012 (2012-10-01), INFORMA HEALTHCARE, UK, pages 2015 - 2023, XP008183236, ISSN: 1029-2403, [retrieved on 20120430], DOI: 10.3109/10428194.2012.673228 *
OISHI JUN ET AL: "Abstract LB-141: Specific and potent silencing of K-Ras by asymmetric silencing RNA (aiRNA) reveals addiction of cancer stem cells to mutant K-Ras amplification", CANCER RESEARCH, vol. 75, no. Suppl. 15, August 2015 (2015-08-01), 106TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-CANCER-RESEARCH (AACR); PHILADELPHIA, PA, USA; APRIL 18 -22, 2015, XP002779233, DOI: 10.1158/1538-7445.AM2015-LB-141 *
SOUKAINA REJIBA ET AL: "K-ras oncogene silencing strategy reduces tumor growth and enhances gemcitabine chemotherapy efficacy for pancreatic cancer treatment", CANCER SCIENCE, vol. 98, no. 7, 1 July 2007 (2007-07-01), pages 1128 - 1136, XP055063526, ISSN: 1347-9032, DOI: 10.1111/j.1349-7006.2007.00506.x *

Also Published As

Publication number Publication date
WO2018098352A2 (fr) 2018-05-31

Similar Documents

Publication Publication Date Title
WO2018098352A3 (fr) Ciblage d'expression du point de contrôle immunitaire induit par kras
MX2017007321A (es) Terapias de combinacion.
PH12017501818A1 (en) Fgfr/pd-1 combination therapy for the treatment of cancer
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX2022001583A (es) Moduladores del receptor de glucosocorticoides para tratar el cancer pancreatico.
MX2017015938A (es) Inhibidores de ezh2 para el tratar linfomas.
MX2018005071A (es) Tratamiento del cancer de pulmon de celulas pequeñas con un inhibidor de parp.
AU2015311681A8 (en) Globin gene therapy for treating hemoglobinopathies
PH12019501010A1 (en) Arginase inhibitor combination therapies
MX2019014761A (es) Manejo de toxicidad para actividad antitumoral de cars.
MX2014011965A (es) Terapia de combinacion con un agente antihialuronano y un taxano orientado a tumor.
MX2015005963A (es) Inhibidores heterociclicos de glutaminasa.
EP4140487A8 (fr) Polythérapie anticancéreuse
MX2020010194A (es) Agente reductor de amoniaco para usarse en el tratamiento de enfermedades asociadas con activacion de celulas estrelladas hepaticas.
WO2018002640A3 (fr) Procédés et compositions de traitement du cancer avec des modulateurs de l'activité de siglec-9
WO2013134407A3 (fr) Activation de procaspase 3 par polythérapie
MX2019013862A (es) Terapia de combinacion.
MX2021008605A (es) Arn terapéutico y anticuerpos anti-pd1 para canceres de tumor sólido en estadio avanzado.
WO2019090347A8 (fr) Inhibiteurs de la voie de l'adénosine pour le traitement du cancer
MX2018000052A (es) Composiciones y métodos para la terapia combinada con virus del dengue y celulas dendríticas.
MX2017012867A (es) Composiciones terapeuticas y metodos de uso para tratar el cancer.
MX2016004285A (es) Tratamiento de tumor por combinacion con minicelulas dirigidas a ligando, biespecificas, cargadas con farmacos e interferon-gamma.
AU2016206832A8 (en) Non-invasive systems and methods for treatment of a host carrying a virus with photoactivatable drugs
WO2016073763A3 (fr) Compositions et procédés de bêta-glucane qui affectent le micro-environnement de la tumeur
EP3998341A3 (fr) Vecteurs adénoviraux

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17817465

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17817465

Country of ref document: EP

Kind code of ref document: A2